Representative Pete Sessions (Republican-Texas) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on September 18th, the Representative disclosed that they had sold between $15,001 and $50,000 in AbbVie stock on September 14th. The trade occurred in the Representative’s “ET IRA” account.
Representative Pete Sessions also recently made the following trade(s):
- Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 9/14/2026.
- Sold $1,001 – $15,000 in shares of Ares Capital (NASDAQ:ARCC) on 7/24/2026.
AbbVie Stock Up 0.4%
NYSE ABBV opened at $265.06 on Tuesday. The company has a market capitalization of $468.31 billion, a price-to-earnings ratio of 74.88, a PEG ratio of 1.19 and a beta of 0.29. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The stock has a fifty day simple moving average of $255.90 and a 200 day simple moving average of $232.37.
AbbVie Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s payout ratio is currently 195.48%.
Key AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: The European Commission approved RINVOQ (upadacitinib) for children ages two and older with active polyarticular juvenile idiopathic arthritis who have not responded adequately to, or cannot tolerate, certain prior treatments. The approval expands RINVOQ’s addressable market in Europe and adds an oral-solution formulation, reinforcing the drug’s role as a growth driver across AbbVie’s immunology portfolio. AbbVie Announces European Commission Approval of RINVOQ for Juvenile Idiopathic Arthritis
- Positive Sentiment: Investor-focused coverage highlighted AbbVie as a dividend stock to buy and hold, citing its cash-generative business, long dividend history and relatively resilient franchise. That endorsement may support demand from income-oriented investors, particularly as the company maintains its 2026 outlook. 3 Dividend Stocks to Buy Before September Ends and Hold Forever
- Neutral Sentiment: AbbVie entered a multiyear collaboration with Iambic to use artificial intelligence for small-molecule drug discovery in immunology, neuroscience and oncology. The agreement could improve pipeline productivity and produce future first- or best-in-class medicines, but the financial impact is uncertain and likely distant because programs remain in the discovery stage. AbbVie and Iambic Announce AI-Driven Drug Discovery Collaboration
Insider Activity
In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.
Hedge Funds Weigh In On AbbVie
A number of institutional investors and hedge funds have recently made changes to their positions in ABBV. ACT Advisors LLC. increased its stake in shares of AbbVie by 2.5% during the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after purchasing an additional 41 shares during the last quarter. Willner & Heller LLC boosted its holdings in AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after purchasing an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC boosted its holdings in AbbVie by 3.1% in the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after purchasing an additional 43 shares in the last quarter. Fielder Capital Group LLC increased its position in AbbVie by 1.7% during the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after buying an additional 43 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC raised its holdings in AbbVie by 0.4% during the second quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock valued at $2,996,000 after buying an additional 43 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on ABBV shares. Bank of America reissued a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Barclays increased their price target on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Morgan Stanley restated an “overweight” rating and set a $296.00 target price on shares of AbbVie in a research report on Monday, August 3rd. Finally, Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $276.64.
Check Out Our Latest Stock Report on ABBV
About Representative Sessions
Pete Sessions (Republican Party) is a member of the U.S. House, representing Texas’ 17th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.
Sessions (Republican Party) ran for re-election to the U.S. House to represent Texas’ 17th Congressional District. He won in the general election on November 5, 2024.
On October 20, 2023, Sessions announced he was running to replace Kevin McCarthy (R) as speaker of the U.S. House in the 118th Congress. Sessions lost the first round of nomination voting on October 24, 2023.
Pete Sessions was born and lives in Waco, Texas. Sessions earned a B.S. from Southwestern University in 1978. Sessions’ career experience includes working as an executive with AT&T.
About AbbVie
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.
AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.
Read More
- Five stocks we like better than AbbVie
- Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong
- Amazon’s $8 Billion Generac Deal Shows AI’s New Power Bottleneck
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
